IBT Finds A Home At Last
This article was originally published in Start Up
Executive Summary
At last, International Biotechnology Trust PLC, the £350 million LSE-listed investment trust, has found a resting place. Two years after IBT's previous manager, Rothschild Asset Management, decided they wanted out of biotech, private equity group Schroder Ventures has been selected by the board of IBT to take up the reins.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?